Universal Vision Biotechnology Co., Ltd. (TPEX:3218)
Taiwan
· Delayed Price · Currency is TWD 133.50
+7.00 (5.53%)
Apr 29, 2026, 9:59 AM CST
TPEX:3218 Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 4,204 | 4,228 | 4,082 | 3,494 | 2,632 | Upgrade
|
| Revenue Growth (YoY) | -0.57% | 3.58% | 16.83% | 32.76% | 28.18% | Upgrade
|
| Cost of Revenue | 1,721 | 1,695 | 1,634 | 1,354 | 995.36 | Upgrade
|
| Gross Profit | 2,483 | 2,533 | 2,448 | 2,140 | 1,636 | Upgrade
|
| Selling, General & Admin | 1,105 | 1,133 | 1,132 | 1,051 | 867.59 | Upgrade
|
| Operating Expenses | 1,102 | 1,135 | 1,137 | 1,059 | 867.91 | Upgrade
|
| Operating Income | 1,380 | 1,398 | 1,312 | 1,081 | 768.54 | Upgrade
|
| Interest Expense | -24.84 | -20.94 | -15.83 | -13.56 | -13.16 | Upgrade
|
| Interest & Investment Income | 67.53 | 39.58 | 19.16 | 6.93 | 4.07 | Upgrade
|
| Currency Exchange Gain (Loss) | -5.51 | 7.9 | -0.06 | 9.8 | -2.57 | Upgrade
|
| Other Non Operating Income (Expenses) | 5.72 | 2.16 | 3.59 | 9.6 | 6.03 | Upgrade
|
| EBT Excluding Unusual Items | 1,423 | 1,427 | 1,319 | 1,094 | 762.91 | Upgrade
|
| Gain (Loss) on Sale of Investments | -61.89 | -100.22 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.62 | -8.92 | -1.37 | -2.22 | -0.22 | Upgrade
|
| Asset Writedown | -16.17 | - | - | - | - | Upgrade
|
| Other Unusual Items | 1.12 | 0.57 | 1.23 | 0.41 | 0.42 | Upgrade
|
| Pretax Income | 1,346 | 1,318 | 1,319 | 1,092 | 763.11 | Upgrade
|
| Income Tax Expense | 290.98 | 267.82 | 254.56 | 223.98 | 152.45 | Upgrade
|
| Earnings From Continuing Operations | 1,055 | 1,050 | 1,064 | 868.11 | 610.66 | Upgrade
|
| Minority Interest in Earnings | -11.96 | 14.5 | -18.93 | -17.58 | -15.23 | Upgrade
|
| Net Income | 1,043 | 1,065 | 1,045 | 850.53 | 595.43 | Upgrade
|
| Net Income to Common | 1,043 | 1,065 | 1,045 | 850.53 | 595.43 | Upgrade
|
| Net Income Growth | -2.07% | 1.88% | 22.88% | 42.84% | 23.22% | Upgrade
|
| Shares Outstanding (Basic) | 85 | 85 | 85 | 85 | 85 | Upgrade
|
| Shares Outstanding (Diluted) | 85 | 85 | 85 | 85 | 85 | Upgrade
|
| Shares Change (YoY) | 0.10% | 0.08% | 0.04% | 0.03% | -0.03% | Upgrade
|
| EPS (Basic) | 12.31 | 12.57 | 12.34 | 10.04 | 7.03 | Upgrade
|
| EPS (Diluted) | 12.26 | 12.53 | 12.31 | 10.02 | 7.02 | Upgrade
|
| EPS Growth | -2.15% | 1.79% | 22.85% | 42.76% | 23.22% | Upgrade
|
| Free Cash Flow | 1,104 | 1,237 | 1,081 | 778.47 | 587.33 | Upgrade
|
| Free Cash Flow Per Share | 12.98 | 14.56 | 12.73 | 9.17 | 6.92 | Upgrade
|
| Dividend Per Share | 7.750 | 7.500 | 7.000 | 5.660 | 4.492 | Upgrade
|
| Dividend Growth | 3.33% | 7.14% | 23.67% | 26.00% | 19.05% | Upgrade
|
| Gross Margin | 59.05% | 59.91% | 59.98% | 61.24% | 62.18% | Upgrade
|
| Operating Margin | 32.83% | 33.06% | 32.14% | 30.94% | 29.20% | Upgrade
|
| Profit Margin | 24.80% | 25.18% | 25.60% | 24.34% | 22.62% | Upgrade
|
| Free Cash Flow Margin | 26.25% | 29.27% | 26.48% | 22.28% | 22.32% | Upgrade
|
| EBITDA | 1,728 | 1,739 | 1,592 | 1,295 | 942.85 | Upgrade
|
| EBITDA Margin | 41.11% | 41.12% | 38.99% | 37.06% | 35.83% | Upgrade
|
| D&A For EBITDA | 347.89 | 340.67 | 279.84 | 213.63 | 174.32 | Upgrade
|
| EBIT | 1,380 | 1,398 | 1,312 | 1,081 | 768.54 | Upgrade
|
| EBIT Margin | 32.83% | 33.06% | 32.14% | 30.94% | 29.20% | Upgrade
|
| Effective Tax Rate | 21.63% | 20.32% | 19.30% | 20.51% | 19.98% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.